Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: CB-839
Sponsor: Calithera Biosciences, Inc